
| Image Class: | skin-invert-image |
| Width: | 215 |
| Tradename: | Vasocon-a |
| Routes Of Administration: | Topical (nasal, eye drops) |
| Atc Prefix: | R01 |
| Atc Suffix: | AC04 |
| Legal Au: | S4 |
| Legal Au Comment: | /Schedule 2[1] |
| Cas Number: | 91-75-8 |
| Pubchem: | 2200 |
| Iuphar Ligand: | 7116 |
| Drugbank: | DB08799 |
| Chemspiderid: | 2115 |
| Unii: | DHA8014SS1 |
| Kegg: | D07458 |
| Chebi: | 84115 |
| Chembl: | 1305 |
| Iupac Name: | N-(4,5-Dihydro-1H-imidazol-2-ylmethyl)-N-(phenylmethyl)aniline |
| C: | 17 |
| H: | 19 |
| N: | 3 |
| Smiles: | N\1=C(\NCC/1)CN(c2ccccc2)Cc3ccccc3 |
| Stdinchi: | 1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19) |
| Stdinchikey: | REYFJDPCWQRWAA-UHFFFAOYSA-N |
Antazoline is a 1st generation antihistamine with anticholinergic properties used to relieve nasal congestion and in eye drops, usually in combination with naphazoline, to relieve the symptoms of allergic conjunctivitis.[2] To treat allergic conjunctivitis, antazoline can be combined in a solution with tetryzoline.[3] The drug is a Histamine H1 receptor antagonist:[4] selectively binding to but not activating the receptor, thereby blocking the actions of endogenous histamine and subsequently leading to the temporary relief of the negative symptoms brought on by histamine.
A 2015 study on people aged 65 years of age or older linked the development of Alzheimer's disease and other forms of dementia to the "higher cumulative" use of first-generation antihistamines, due to their anticholinergic properties.[5]